Serum matrix metalloproteinase-9:tissue inhibitor of metalloproteinase- 1 ratio correlates with steroid responsiveness in moderate to severe asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 2, 1999, Pages 596-602

  Bossé, Marc ^b   Chakir, Jamila ^b   Rouabhia, Mahmoud ^b   Boulet, Louis Philippe ^b   Audette, Marie ^b   Laviolette, Michel ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GELATINASE B; METHYLPREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; ASTHMA; BLOOD LEVEL; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FIBROGENESIS; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOASSAY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0000692136     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.2.9802045     Document Type: Article

References (35)

1. Matrisian, L. M. 1990. Metalloproteinases and their inhibitors in matrix remodeling. Trend. Genet. 6:121-125.
2. Collier, I. E., S. M. Wilhelm, A. Z. Eisen, B. L. Marmer, G. A. Grant, J. L. Seltzer, A. Kronberger, C. S. He, E. A. Bauer, and G. I. Goldberg. 1988. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 263:6579-6587.
3. Wilhelm, S. M., I. E. Collier, B. L. Marmer, A. Z. Eisen, G. A. Grant, and G. I. Goldberg. 1989. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:17213-17221.
4. Okada, S., H. Kita, T. J. George, G. Gleich, and K. M. Leiferman. 1997. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am. J. Respir. Cell Mol. Biol. 17:519-528.
5. Leppert, D., E. Waubant, R. Galardy, N. W. Bunnett, and S. L. Hauser. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:4379-4389.
6. Stetler-Stevensen, W. G., H. C. Krutzsch, and L. A. Liotta. 1989. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264:17374-17378.
7. Goldberg, G. I., B. L. Marmer, G. A. Grant, A. Z. Eisen, S. Wilhelm, and C. S. He. 1989. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc. Natl. Acad. Sci. U.S.A. 86:8207-8211.
8. Kikuchi, K., T. Kadono, M. Furue, and K. Tamaki. 1997. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J. Invest. Dermatol. 108:281-284.
9. Bullen, E. C., M. T. Longaker, D. L. Updike, R. Benton, D. Ladin, Z. Hou, and E. W. Howard. 1995. Tissue inhibitor of metalloproleinases-1 is decreased and activated gelatinases are increased in chronic wounds. J. Invest. Dermatol. 104:236-240.
10. Gruber, B. L., D. Sorbi, D. L. French, M. J. Marchese, G. J. Nuovo, R. R. Kew, and L. A. Arbeit. 1996. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin. Immunol. Immunopathol. 78:161-171.
11. Kikuchi, K., M. Kubo, S. Sato, M. Fujimoto, and K. Tamaki. 1995. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J. Am. Acad. Dermatol. 33:973-978.
12. Iredale, J. P., R. C. Benyon, M. J. Arthur, W. F. Ferris, R. Alcolado, P. J. Winwood, N. Clark, and G. Murphy. 1996. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 24:176-184.
13. Kasahara, A., N. Hayashi, K. Mochizuki, M. Oshita, K. Katayama, M. Kato, M. Masuzawa, H. Yoshihara, M. Naito, T. Miyamoto, A. Inoue, A. Asai, T. Hijioka, H. Fusamoto, and T. Kamada. 1997. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with hepatitis C: relationship to interferon response. J. Hepatol. 26:574-583.
14. Nuovo, G. J., P. B. MacConnell, A. Simsir, F. Valea, and D. L. French. 1995. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:267-275.
15. Beasley, R., W. Roche, and S. T. Holgale. 1989. Inflammatory processes in bronchial asthma. Drugs 37(Suppl. 1):117-122.
16. Bousquet, J., P. Chanez, J. Y. Lacoste, R. White, P. Vic, P. Godard, and F. B. Michel. 1992. Asthma: a disease remodeling the airways. Allergy 47:3-11.
17. The Thomas L. Petty 37th Aspen Lung Conference. 1995. Asthma - structure and function: proceedings. Chest 107:s85-s169.
18. Jeffery, P. K., R. W. Godfrey, E. Adelroth, F. Nelson, A. Rogers, and S. A. Johansson. 1992. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am. Rev. Respir. Dis. 145:890-899.
19. Laitinen, L. A., and A. Laitinen. 1996. Remodeling of asthmatic airways by glucocorticosteroids. J. Allergy Clin. Immunol. 97:153-158.
20. Lundgren, R., M. Soderberg, P. Horstedt, and R. Stenling. 1988. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur. Respir. J. 1:883-889.
21. Barnes, P. J., and I. M. Adcock. 1997. Glucocorticoid receptors. In R. G. Crystal and J. B. West, editors. The Lung. Lippincott-Raven Publishers, Philadelphia. 37-55.
22. Bridges, A. J., K. C. Hsu, A. A. Dias-Arias, and V. Chechani. 1992. Bronchiolitis obliterans organizing pneumonia and scleroderma. J. Rheumatol. 19:1136-1140.
23. Chetta, A., A. Foresi, D. M. Del, G. Bertorelli, A. Pesci, and D. Olivieri. 1997. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 111:852-857.
24. Roche, W. R., R. Beasley, J. H. Williams, and S. T. Holgate. 1989. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1:520-524.
25. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. 1987. Am. Rev. Respir. Dis. 136:225-244.
26. Corrigan, C. J., P. H. Brown, N. C. Barnes, S. J. Szefler, J. J. Tsai, A. J. Frew, and A. B. Kay. 1991. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am. Rev. Respir. Dis. 144:1016-1025.
27. Stricklin, G. P., J. J. Jeffery, W. T. Roswit, and A. Z. Eisen. 1983. Human skin fibroblast procollagenase: mechanism of activation by organomercurials and trypsin. Biochemistry 22:61-68.
28. St-Pierre, Y., M. Desrosiers, P. Tremblay, and P. O. Esteve. 1996. Flow cytometric analysis of gelatinase B (MMP-9) activity using immobilized fluorescent substrate on microspheres. Cytometry Suppl. 25:374-380.
29. Zar, J. H. 1984. Biostatistical Analysis, 2nd ed. Prentice-Hall, Englewood Cliffs, NJ. 222-225.
30. Corcoran, M. L., and W. G. Stetler-Stevenson. 1995. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J. Biol. Chem. 270:13453-13459.
31. Delacourt, C., M. Bourgeois, M. P. D'Ortho, C. Doit, P. Scheinmann, J. Navarro, A. Harf, D. J. Hartmann, and C. Lafuma. 1995. Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 152:765-774.
32. Ohno, I., H. Ohtani, Y. Nitta, J. Suzuki, H. Hoshi, M. Honma, S. Isoyama, Y. Tanno, G. Tamura, K. Yamauchi, H. Nagura, and K. Shirato. 1997. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol. 16:212-219.
33. Pauwels, R. A., C. G. Löfdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, and A. Ullman. 1997. Effects of inhaled formoterol and budesonide on excerbations of asthma. N. Engl. J. Med. 337:1405-1411.
34. Spahn, J. D., D. Y. Leung, W. Surs, R. J. Harbeck, S. Nimmagadda, and S. J. Szefler. 1995. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am. J. Respir. Crit. Care Med. 151:1709-1714.
35. Woolcock, A. J. 1996. Corticosteroid-resistant asthma: definitions. Am. J. Respir. Crit. Care Med. 154(Suppl.):S45-S48.